NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Diagnostics & Research · USD

RadNet, Inc. (RDNT) Stock Analysis

RadNet, Inc. (RDNT) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RDNT

$68.41

−$1.24 (−1.78%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RDNT with… →

RDNT Key Statistics

As of Oct 21, 2026
Trading
Open
$69.48
Previous Close
$69.65
Day's Range
68.06–70.26
52-Week Range
50.82–85.84
Volume
458.31K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.41
Valuation
Market Cap
$5.38B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
77.15
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.96
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.37
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.27
Financials (FY)
Revenue (FY)
$2.04B+11.51%
Net Income (FY)
−$18.65M−767.81%
Profit marginThe share of revenue left as profit after all costs and taxes.
−0.93%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
78.70M
1-Year Return
−14.66%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
682.85K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RDNT closed at $68.41, −14.66% over 1 year.

RadNet, Inc. (RDNT) has a market capitalization of $5.38B.

In fiscal 2025, RDNT reported revenue of $2.04B.

RDNT Stock Return by Calendar Year

RadNet, Inc. (RDNT) 10-year return: what $10,000 became

1 year
$10,000 $8,534
−14.66%
5 years
$10,000 $22,452
+124.52%
10 years
$10,000 $87,036
+770.36%

If you had invested $10,000 in RadNet, Inc. (RDNT) 10 years ago, at the close on October 21, 2016, it would have been worth $87,036 at the close on October 21, 2026: +770.36% in total, +24.16% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−4.12%
2025+2.16%
2024+100.86%
2023+84.65%
2022−37.46%
2021+53.86%
2020−3.60%
2019+99.61%
2018+0.69%
2017+56.59%
2016 (partial year)+8.04%

As of October 21, 2026.

RDNT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.04B−$18.65M−0.9%
2024$1.83B$2.79M0.2%
2023$1.62B$3.04M0.2%
2022$1.43B$10.65M0.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.04B$235.49M$83.36M−$18.65M−0.9%
2024$1.83B$249.12M$111.28M$2.79M0.2%
2023$1.62B$221.39M$93.00M$3.04M0.2%
2022$1.43B$165.72M$49.84M$10.65M0.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RDNT Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricRDNTDiagnostics & Research medianvs median
P/S ratio2.375.2355% below
Profit margin−0.93%−0.93%0.0 pts above

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

RadNet, Inc. (RDNT) carries a market capitalisation of $5.38B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. Headcount on file is 11,000.

The most recent close on file for RDNT is $68.41, dated October 21, 2026. That is −$1.24 (−1.78%) against the previous close. Over the past 52 weeks the price has ranged from $50.82 to $85.84. The latest close sits 34.61% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.04B. That is +11.51% against the prior fiscal year, when revenue was $1.83B. The same year closed with a net loss of $18.65M. The reported profit margin is −0.93%. Trailing earnings per share are −0.27.

Across the 4 fiscal years on file, revenue moves from $1.43B in 2022 to $2.04B in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 77.15. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.96. The price-to-sales ratio is 2.37. On price-to-sales that is 54.6% below the Diagnostics & Research median of 5.23. The medians here are taken across 45 Diagnostics & Research companies that report the metric.

Beta against the wider market is reported at 1.41. Annualized volatility over the trailing 10 years is 48.48%. The trailing one-year total return is −14.66%. Across 10 years the annualized return works out at +24.16%.

Growth & Income

No dividend is on file for RDNT.

2026 is still running; the total return is −4.12% year to date. Across the complete calendar years on file, 2024 returned +100.86% and 2022 returned −37.46%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

RadNet, Inc. (RDNT) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
RadNet, Inc. RDNT $5.38B —
Thermo Fisher Scientific Inc. TMO $256.61B 37.4
Danaher Corporation DHR $164.40B 41.7
Natera, Inc. NTRA $59.59B —

The Diagnostics & Research industry average P/E ratio is 37.6x. RadNet, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

 DHR

Danaher Corporation

$164.40B

 NTRA

Natera, Inc.

$59.59B

 A

Agilent Technologies, Inc.

$50.12B

 IQV

IQVIA Holdings Inc.

$45.53B

 WAT

Waters Corporation

$44.92B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About RadNet, Inc.

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Visit website →